05
Jun

After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline’s cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.

…read more

Source: GlaxoSmithKline tees up another huge cardio PhIII after darapladib flop

    

0 No comments